Company / Accounts Receivable
Ultragenyx Pharmaceutical Inc. Accounts Receivable History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$158.0M
FY2025
5-year range
$28.4M / $158.0M
FY2021-FY2025
Trend
+29.5%
vs FY2024
Sector context
#38 of 113
Health Care
What the data says
At $158M, Ultragenyx Pharmaceutical Inc.'s accounts receivable ranks #38 of 113 in the Health Care sector. Accounts Receivable has increased for 5 consecutive years, from $23M in FY2020 to $158M in FY2025.
Based on SEC 10-K filings.
$158M in FY2025 with a 5-year CAGR of +46.9%.
Improved from $73M to $158M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +57.5%
- 5-Year CAGR
- +46.9%
- 10-Year CAGR
- -
Sector benchmark
#38 of 113 in Health CareTop 34% of 113This company $158.0M Sector average $1.1B
▼
-86.1% below sector average
Key checks
Key Insights
- Ultragenyx Pharmaceutical Inc.'s accounts receivable has grown for 5 consecutive years.
- 5-year CAGR of +46.9%, indicating consistent growth.
- In FY2025, accounts receivable increased 29.5% year-over-year.
- Ranks #38 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -2.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $158.0M | +29.5% |
| FY2024 | $122.0M | +66.2% |
| FY2023 | $73.4M | +81.5% |
| FY2022 | $40.4M | +42.3% |
| FY2021 | $28.4M | +23.1% |
| FY2020 | $23.1M | -29.7% |
| FY2019 | $32.8M | +157.8% |
| FY2018 | $12.7M | +146.3% |
| FY2017 | $5.2M | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026